Free Newsletter
Who should Pfizer buy?
Biogen Idec's sudden step onto the sale block has set off a frenzy of buyout talk. Will Pfizer buy it? According to the Wall Street Journal, Pfizer considered a Biogen deal two years ago and passed. What about Biogen's crosstown rival Genzyme, whose stock jumped on the Biogen news because it's a biotech ripe for Big Pharma plucking? It might be a better fit for Pfizer, some analysts say. Pfizer, of course, isn't talking.
- here's more about Pfizer's pass on Biogen two years ago
- check out this speculation about a Pfizer-Genzyme marriage
ALSO: Who will buy Biogen Idec? Poll
Related Articles:
Biogen Idec in play after Icahn makes his move. Report
Boston officials herald big Genzyme expansion. Report
Pfizer-Sanofi match not made in heaven? Report
Pfizer, Wyeth merger bad idea? Report
Read more on: Pfizer | Biogen Idec | Genzyme
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: